resTORbio, Inc. (TORC)
Stock Price:
$2.40 USD
0.05 (1.91%)
Updated Jul 16, 2020 11:17 AM EDT - Market open
Key Info
| Market Cap |
87.29M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-78.71M |
| Shares Out |
36.45M |
| EPS (ttm) |
-2.18 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 16, 2020 |
| Last Price |
$2.40 |
| Previous Close |
$2.35 |
| Change ($) |
0.05 |
| Change (%) |
1.91% |
| Day's Open |
2.35 |
| Day's Range |
2.31 - 2.47 |
| Day's Volume |
332,602 |
| 52-Week Range |
0.86 - 11.96 |
More Stats
| Market Cap |
87.29M |
| Enterprise Value |
10.70M |
| Earnings Date (est) |
Aug 6, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
36.45M |
| Float |
25.82M |
| EPS (basic) |
-2.28 |
| EPS (diluted) |
-2.18 |
| FCF / Share |
-2.11 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
560,879 |
| Short Ratio |
0.57 |
| Short % of Float |
2.01% |
| Beta |
2.59 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
1.09 |
| Revenue |
n/a |
| Operating Income |
-81.15M |
| Net Income |
-78.71M |
| Free Cash Flow |
-76.92M |
| Net Cash |
76.59M |
| Net Cash / Share |
2.10 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-45.04% |
| ROE |
-72.85% |
| ROIC |
-124.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
4.00
Current: 2.40
High
4.00
Target: 4.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | - | - | - |
| Operating Income | -85.46 | -39.71 | -18.88 |
| Net Income | -82.74 | -37.61 | -33.78 |
| Shares Outstanding | 34.31 | 26.44 | 4.01 |
| Earnings Per Share | -2.41 | -1.42 | -8.42 |
| Operating Cash Flow | -73.68 | -35.45 | -10.99 |
| Capital Expenditures | -0.27 | -0.36 | -0.04 |
| Free Cash Flow | -73.95 | -35.81 | -11.03 |
| Cash & Equivalents | 91.72 | 108 | 53.35 |
| Net Cash / Debt | 91.72 | 108 | 53.35 |
| Assets | 93.91 | 110 | 55.19 |
| Liabilities | 12.21 | 5.74 | 5.50 |
| Book Value | 81.70 | 104 | -31.93 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
resTORbio, Inc. |
| Country |
United States |
| Employees |
12 |
| CEO |
Chen Schor |
Stock Information
| Ticker Symbol |
TORC |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: TORC |
| IPO Date |
January 26, 2018 |
Description
resTORbio, Inc., a clinical-stage biopharmaceutical company, develops medicine to treat aging-related diseases. Its lead program is selectively inhibits the target of rapamycin complex 1 (TORC1), an evolutionary conserved pathway that contributes to the age-related decline in function of various organ systems, including immune, neurologic, and cardiac functions. The company's lead drug candidate is RTB101, an oral, selective, and potent inhibitor of TORC1 that is in Phase 1b/2a clinical trial for the treatment of Parkinson's disease, as well as to treat neurodegenerative diseases. resTORbio, Inc. was founded in 2016 and is headquartered in Boston, Massachusetts.